Teachers Advisors LLC Raises Position in Jazz Pharmaceuticals (JAZZ)

Teachers Advisors LLC grew its position in shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 601,785 shares of the specialty pharmaceutical company’s stock after acquiring an additional 83,426 shares during the period. Teachers Advisors LLC owned about 1.00% of Jazz Pharmaceuticals worth $81,030,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of JAZZ. California State Teachers Retirement System bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at about $449,000. Nationwide Fund Advisors raised its stake in shares of Jazz Pharmaceuticals by 16.7% during the third quarter. Nationwide Fund Advisors now owns 24,500 shares of the specialty pharmaceutical company’s stock valued at $3,583,000 after acquiring an additional 3,500 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 177.7% during the third quarter. Victory Capital Management Inc. now owns 9,468 shares of the specialty pharmaceutical company’s stock valued at $1,385,000 after acquiring an additional 6,058 shares during the last quarter. State of Wisconsin Investment Board bought a new position in shares of Jazz Pharmaceuticals during the third quarter valued at about $6,193,000. Finally, Swiss National Bank raised its stake in shares of Jazz Pharmaceuticals by 1.3% during the third quarter. Swiss National Bank now owns 221,100 shares of the specialty pharmaceutical company’s stock valued at $32,336,000 after acquiring an additional 2,800 shares during the last quarter. 91.20% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP Paul Treacy sold 877 shares of the stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $139.62, for a total transaction of $122,446.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $148.65, for a total transaction of $29,730.00. Following the sale, the executive vice president now owns 21,669 shares in the company, valued at approximately $3,221,096.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,758 shares of company stock worth $2,031,181. Corporate insiders own 4.30% of the company’s stock.

JAZZ traded down $2.70 during midday trading on Friday, reaching $149.91. The company’s stock had a trading volume of 474,034 shares, compared to its average volume of 426,519. The stock has a market cap of $9,126.60, a PE ratio of 15.68, a price-to-earnings-growth ratio of 0.80 and a beta of 0.97. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.15 and a current ratio of 3.29. Jazz Pharmaceuticals has a 1 year low of $128.58 and a 1 year high of $163.75.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.73 by ($0.15). The business had revenue of $436.40 million during the quarter, compared to analysts’ expectations of $440.91 million. Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. equities research analysts predict that Jazz Pharmaceuticals will post 11.48 EPS for the current year.

Several brokerages have recently commented on JAZZ. Seaport Global Securities set a $175.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. HC Wainwright reaffirmed a “neutral” rating and set a $160.00 price objective (up from $150.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 23rd. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $128.58 to $163.75 in a research note on Monday, March 19th. BidaskClub raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 13th. Finally, Piper Jaffray reissued a “buy” rating and issued a $201.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $180.78.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/teachers-advisors-llc-grows-holdings-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply